 鲜花( 85)  鸡蛋( 2)
|

楼主 |
发表于 2015-2-28 21:48
|
显示全部楼层
Stock soars after Cold-fX wins crucial approval3 B# ~9 t5 { Z6 m9 @, u x
# n- X4 L/ @! j2 u3 i, l5 Q
EDMONTON - CV Technologies Inc. shares rose nearly 60 per cent Thursday after Health Canada approved the claims at the core of the company's marketing of its cold and flu drug Cold-fX.7 j8 \% X' a* V# }6 h# b
0 g, k7 }* h1 W1 R! U' S# C3 b3 V' I
BY THE EDMONTON JOURNAL FEBRUARY 16, 2007/ k( t& k- r* O
6 D1 R* x' J! D( x& [ . k" K+ x: f; r9 s) b6 \ W
EDMONTON - CV Technologies Inc. SHARES rose nearly 60 per cent Thursday after Health Canada approved the claims at the core of the company's marketing of its cold and flu drug Cold-fX.
# n5 Z$ @ D0 T5 m' v8 w c+ M
3 R4 [$ G5 d3 y8 XThe agency said CV Technologies can continue to market Cold-fX as helping "to reduce the frequency, severity and duration of cold and flu symptoms by boosting the IMMUNE SYSTEM."% a. L( I( Q) Y# A0 j: [, x
. Z4 _2 N: D7 i& k1 oThe APPROVAL follows a review of seven clinical trials and more than 10 years of research about the product.
. N, o% q3 u! B( I9 {$ _( D) l) I0 s$ ^0 _; ?) k& r6 O% J2 G
It should create even more confidence among consumers and medical professionals that the product works, CEO Jacqueline Shan said Thursday.. |5 Y/ f+ H. J$ T, t4 L9 x
) y4 j" {. a) Z, ?( ~# r6 T
It certainly instilled confidence in the market, as shares closed at $2.90 on THE TORONTO STOCK EXCHANGE, up $1.08 on a volume of 4.6 million.
/ t6 s9 z+ r; ^# R7 s2 e9 ^2 c7 _$ U& g* s- W
"As a scientist, it's one of the highlights of my CAREER," Shan said.& T9 J; l) W1 `# r8 z
8 I1 w$ r% H/ w+ x4 [: c; }3 a"This approval is a breakthrough in realizing our vision of being a global leader in developing products for disease prevention."- g" N0 |7 D9 @; j% K2 `
3 x9 R( [8 _) P* K( j& e4 LIt's Cold-fX's strongest medical recognition to date, said Shan. It means the company can advertise the HEALTH BENEFITS more effectively to consumers and health professionals, she said.
: H; R( S' ~# b: x: y
* t2 v" v' l' F1 Y4 V! q: wGinseng-based Cold-fX is already the top-selling cold and flu treatment in Canada, but Shan said there is plenty of room for more growth. K X. z" ^5 x y S/ U: J9 ~
% P) f }1 ?; n0 q6 fThe approval will also help raise the product's PROFILE in the lucrative U.S. market, which Cold-fX entered in October. The move came with a new marketing push, using former Oilers superstar Mark Messier as its spokesman./ M+ b# j* i8 k, X. A$ d. d- z
& A' _0 R& m3 e$ |! k& ^9 a
) a- I# m$ M+ ~' K# Z- h9 c
http://www.canada.com/story.html ... 9-be80-f40f1426f662 |
|